Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Birte Wolff

Gynecology Seattle, WA Medical Doctor

NPI 1194091074 CMS profile 1768297

600 Broadway, Ste 400, Seattle, WA 98122

Open in the dashboard

General payments

$635

27 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Birte Wolff of Seattle, WA is reported in the CMS Open Payments database as having received $635 across 27 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $160 3
2024 General $69 3
2023 General $40 1
2022 General $12 1
2021 General $223 12
2019 General $132 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Birte Wolff
  • Gynecology median
  • Middle half of Gynecology
  • National median

In program year 2025, general payments to Birte Wolff were reported at $160. Among 1,279 Gynecology profiles paid that year, the median was $162 and the middle half received between $56 and $501.

Show as a table
Year Birte Wolff Gynecology median Middle half National median
2019 $132 $199 $66–$472 $163
2020 $0 $114 $42–$287 $114
2021 $223 $141 $42–$430 $132
2022 $12 $173 $52–$532 $149
2023 $40 $170 $57–$501 $160
2024 $69 $157 $50–$424 $164
2025 $160 $162 $56–$501 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $153 6 payments
  2. Medtronic, Inc. $152 3 payments
  3. Boston Scientific Corporation $70 4 payments
  4. Myovant Sciences Inc. $58 2 payments
  5. Agile Therapeutics, Inc. $39 2 payments
  6. Hologic, LLC $39 2 payments
  7. Organon LLC $31 2 payments
  8. Astellas Pharma US Inc $24 1 payment
  9. ConvaTec Inc. $17 1 payment
  10. TherapeuticsMD, Inc. $14 1 payment
  11. Other $37 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $635 27 payments
Products named General payments · program years 2019–2025
  1. INTERSTIM $152 3 payments
  2. Orilissa $84 4 payments
  3. LILETTA $69 2 payments
  4. MYFEMBREE $58 2 payments
  5. Twirla $39 2 payments
  6. Axonics $36 2 payments
  7. MYRBETRIQ $24 1 payment
  8. ACESSA PROVU SYSTEM $24 1 payment
  9. SOLYX $20 1 payment
  10. NEXPLANON $20 1 payment
  11. Other $139 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

420

Median for Obstetrics & Gynecology: 65

Drug cost

$117,243

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

57.9%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 72 $51,733
Gemtesa Vibegron Brand 63 $43,383
Estring Estradiol Brand 24 $12,748
Estradiol Generic 61 $4,673
Methenamine Hippurate Generic 52 $3,008
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 35 $582
Clobetasol Propionate Generic 24 $388
Solifenacin Succinate Generic 17 $305
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 33 $193
Cephalexin Generic 23 $174

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$105,667

Medicare's payments for the services billed

Medicare patients

157

Average age 76

Services billed

1,440

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Arthritis 51%
Osteoporosis 29%
Ischemic heart disease 20%
Chronic kidney disease 18%
Depression 18%
Diabetes 12%
Atrial fibrillation 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

27 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record